STOCK TITAN

Arcturus: Meiji Seika Pharma reports 7.88% passive stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Meiji Seika Pharma Co., Ltd. reported beneficial ownership in Arcturus Therapeutics Holdings Inc. of 2,466,395 shares issuable to and to be held directly by Meiji, representing 7.88% of the class. Meiji reported sole voting and dispositive power over the shares, with zero shared voting or dispositive power.

Meiji based the percentage on 28,822,514 shares outstanding as of November 3, 2026, plus the 2,466,395 shares issuable under a Securities Purchase Agreement dated November 16, 2026, for a stated total of 31,288,909 shares.

Beneficially owned shares 2,466,395 shares Shares issuable to and to be held directly by Meiji Seika Pharma
Ownership percentage 7.88% Percentage of the class reported by Meiji Seika Pharma
Shares outstanding 28,822,514 shares As of November 3, 2026
Stated share total for ownership calculation 31,288,909 shares Includes 28,822,514 shares outstanding and 2,466,395 shares issuable under the Securities Purchase Agreement
beneficially owned regulatory
"Amount beneficially owned: 2,466,395 Shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole voting power regulatory
"Sole Voting Power 2,466,395.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power regulatory
"Sole Dispositive Power 2,466,395.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Shares issuable technical
"2,466,395 Shares issuable to, and to be held directly"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ARCT shares does Meiji Seika Pharma report beneficially owning?

Meiji reports 2,466,395 shares issuable to and to be held directly by it, equal to 7.88% of the class.

How did Meiji Seika Pharma calculate its 7.88% ARCT ownership?

It used 31,288,909 shares as the stated total: 28,822,514 shares outstanding as of November 3, 2026, plus 2,466,395 shares issuable under the Securities Purchase Agreement dated November 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





03969T109

(CUSIP Number)
11/16/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: With respect to Rows 5 through 9 and Row 11 above, the amounts reported reflect 2,466,395 shares of Common Stock issuable to, and to be held directly by, the Reporting Person.


SCHEDULE 13G



Meiji Seika Pharma Co., Ltd.
Signature:/s/ Kenshi Murase
Name/Title:Kenshi Murase, Director
Date:11/16/2026

Keep reading